In our present work, we found that Trim31 has the ability to suppress liver steatosis and improve insulin signaling and hepatic inflammation by promoting Rhbdf2 degradation via K48-linked ubiquitination, further restraining Rhbdf2-MAP3K7 activity and downstream events. Here, MAP3K7 is linked to fatty liver disease.